New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3.
The dupilumab CSU data from the LIBERT-CSU CUPID phase 3 study program (Study A and Study C) will be part of one of several Sanofi presentations in partnership with Regeneron.
New analyses from Sanofi’s extensive immunology pipeline, including the RILECSU phase 2 study evaluating rilzabrutinib, a novel oral BTK inhibitor, in adult patients with moderate-to-severe CSU, will also be presented.
“Our robust presence at AAAAI emphasizes the progress of our clinical development in immunology and underscores our commitment to transforming treatment paradigms in immunoscience,” Alyssa Johnson, MD, PhD, Sanofi’s Global Therapeutic Area Head, Immunology and Oncology Development, said in a press release. “We look forward to sharing these data across multiple disease areas, building upon the body of clinical evidence supporting the breadth of Dupixent in conditions driven by type 2 inflammation and exemplifying the potential of our pipeline medicines.”
Sanofi's posters for atopic dermatitis and CSU are:
Atopic dermatitis | ||
Berdyshev | Pediatric Atopic Dermatitis Is Associated With More Rapid Recovery of Protein Bound Ceramides After Treatment With Dupilumab | Poster #625 |
Goleva | The Abnormal Metabolomic Activity in Atopic Dermatitis Skin Is Restored With Dupilumab | Poster #611 |
Irvine | Growth Analysis in Children Aged 6 to 11 Years and Adolescents Aged 12 to 17 Years With Moderate-To-Severe Atopic Dermatitis and Impact of 16 Weeks of Dupilumab Treatment on Height | Poster #639 |
Chronic spontaneous urticaria | ||
Casale | Dupilumab Improves Signs And Symptoms Of Chronic Spontaneous Urticaria Regardless Of Baseline Body Mass Index | Poster #TBD |
Gimenez-Arnau | Dupilumab Improves Itch And Urticaria Activity in Patients With Chronic Spontaneous Urticaria: Pooled Results From Two Phase 3 Trials (LIBERTY-CSU CUPID Study A and Study C) | Late-Breaking Poster |
Bernstein | Real-world Treatment Patterns Amongst Patients with Chronic Spontaneous Urticaria Initiating Advanced Therapies | Poster #597 |
Bernstein | Effects of Rilzabrutinib on Angioedema over 12 Weeks: Results from the Phase 2 RILECSU Trial in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria | Poster #694 |
Talia | Rilzabrutinib Improves Chronic Spontaneous Urticaria in Patients With and Without Allergic Comorbidities: A Subgroup Analysis From the RILECSU Study | Poster #694 |